Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: FLOVENT HFA

« Back to Dashboard

Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from four suppliers. There are eighteen patents protecting this drug.

The generic ingredient in FLOVENT HFA is fluticasone propionate. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Summary for Tradename: FLOVENT HFA

Suppliers: see list4
2013 Sales:$1,050,009,000

Pharmacology for Tradename: FLOVENT HFA

Clinical Trials for: FLOVENT HFA

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
Status: Completed Condition: Asthma

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Status: Recruiting Condition: Asthma

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma
Status: Completed Condition: Asthma

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
Status: Completed Condition: Asthma

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
Status: Recruiting Condition: Mild to Moderate Asthma

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids
Status: Completed Condition: Asthma

Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution
Status: Not yet recruiting Condition: Asthma

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler
Status: Completed Condition: Asthma

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
Status: Completed Condition: Asthma

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Status: Recruiting Condition: Eosinophilic Esophagitis

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes6,743,413*PED<disabled>Y<disabled>
Glaxo Grp Ltd
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes7,500,444*PED<disabled>Y<disabled>
Glaxo Grp Ltd
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes7,107,986*PED<disabled>Y<disabled>
Glaxo Grp Ltd
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes6,315,173*PED<disabled>Y<disabled>
Glaxo Grp Ltd
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes6,596,260*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology